CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 669 enrolled
Drug / intervention
Phase 1: FARAPULSE Ablation System +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05443594
NCT05443594N/ACompleted
CompareCT.gov

A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation

Boston Scientific Corporation·interventional·Posted Jul 5, 2022·Updated Dec 16, 2025

In Brief

A clinical study evaluating Phase 1: FARAPULSE Ablation System and Phase 2: FARAPULSE Ablation System for Persistent Atrial Fibrillation. Completed, enrolled 669 participants across 44 sites in 4 countries.

Detailed Summary

The objective of the ADVANTAGE AF Study is to establish the safety and effectiveness of the FARAPULSE Pulsed Field Ablation System (FARAPULSE PFA System) for treatment of drug resistant, symptomatic persistent atrial fibrillation (PersAF).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPersistent Atrial Fibrillation
CountriesBelgium, Canada, Spain, United States
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJul 5, 2022
Enrollment StartFeb 28, 2023
Primary CompletionFeb 11, 2025
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 4.0 years ago

Interventions

Phase 1: FARAPULSE Ablation Systemdevice

PHASE 1: Pulsed Field Ablation to isolate the Pulmonary Veins and Posterior Wall using the FARAPULSE Ablation System.

Phase 2: FARAPULSE Ablation Systemdevice

PHASE 2: Pulsed Field Ablation to isolate the Pulmonary Veins, Posterior Wall and Cavo-Tricuspid Isthmus using the FARAPULSE Ablation System.